Zoetis (NYSE:ZTS – Get Rating) had its price target decreased by analysts at The Goldman Sachs Group from $208.00 to $202.00 in a research note issued to investors on Thursday, The Fly reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s price objective points to a potential upside of 14.61% from the stock’s current price.
Several other analysts also recently weighed in on the company. Piper Sandler assumed coverage on Zoetis in a research report on Monday, July 11th. They set an “overweight” rating and a $205.00 price target for the company. Stifel Nicolaus reduced their price target on shares of Zoetis from $275.00 to $225.00 and set a “buy” rating for the company in a research note on Friday, June 24th. Finally, StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 26th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Zoetis presently has an average rating of “Moderate Buy” and an average price target of $224.88.
Zoetis Stock Performance
Zoetis stock opened at $176.25 on Thursday. The company has a current ratio of 2.25, a quick ratio of 1.58 and a debt-to-equity ratio of 1.12. The stock has a 50 day moving average of $168.35 and a 200-day moving average of $184.30. The stock has a market cap of $82.95 billion, a P/E ratio of 40.42, a price-to-earnings-growth ratio of 2.88 and a beta of 0.73. Zoetis has a 52 week low of $154.18 and a 52 week high of $249.27.
Ad Chaikin Analytics (leads)
Unlock Wall Street’s Secret Logic with This NEW system
Get a glimpse into a one-of-a-kind system built by a 50-year Wall Street veteran. A new way to see which stocks could soon be rated a “BUY” across Wall Street and shoot up. Learn how you could predict TOMORROW’s stock ratings on Wall Street.
Zoetis (NYSE:ZTS – Get Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.10. The firm had revenue of $2 billion for the quarter, compared to the consensus estimate of $1.98 billion. Zoetis had a net margin of 26.27% and a return on equity of 49.62%. The firm’s revenue was up 6.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.26 EPS. On average, analysts expect that Zoetis will post 5.05 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, EVP Roxanne Lagano sold 2,167 shares of the company’s stock in a transaction on Tuesday, April 26th. The stock was sold at an average price of $178.96, for a total transaction of $387,806.32. Following the transaction, the executive vice president now directly owns 23,687 shares of the company’s stock, valued at $4,239,025.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Zoetis news, EVP Roxanne Lagano sold 2,167 shares of Zoetis stock in a transaction dated Tuesday, April 26th. The stock was sold at an average price of $178.96, for a total transaction of $387,806.32. Following the transaction, the executive vice president now owns 23,687 shares of the company’s stock, valued at approximately $4,239,025.52. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Kristin C. Peck sold 311 shares of the stock in a transaction that occurred on Thursday, July 7th. The stock was sold at an average price of $180.00, for a total transaction of $55,980.00. Following the completion of the sale, the chief executive officer now directly owns 39,743 shares of the company’s stock, valued at $7,153,740. The disclosure for this sale can be found here. In the last three months, insiders have sold 8,667 shares of company stock worth $1,503,321. Corporate insiders own 0.12% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the business. Hunter Perkins Capital Management LLC lifted its position in shares of Zoetis by 125.0% in the 2nd quarter. Hunter Perkins Capital Management LLC now owns 3,600 shares of the company’s stock worth $619,000 after acquiring an additional 2,000 shares during the period. Wealthfront Advisers LLC boosted its stake in Zoetis by 25.6% in the 2nd quarter. Wealthfront Advisers LLC now owns 42,633 shares of the company’s stock valued at $7,328,000 after buying an additional 8,699 shares in the last quarter. Values First Advisors Inc. grew its position in Zoetis by 8.9% in the second quarter. Values First Advisors Inc. now owns 1,744 shares of the company’s stock valued at $300,000 after acquiring an additional 143 shares during the period. Trust Co. of Vermont raised its stake in Zoetis by 13.2% during the second quarter. Trust Co. of Vermont now owns 1,234 shares of the company’s stock worth $212,000 after acquiring an additional 144 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its stake in shares of Zoetis by 13.2% in the 2nd quarter. Commonwealth Equity Services LLC now owns 143,774 shares of the company’s stock valued at $24,713,000 after purchasing an additional 16,741 shares in the last quarter. 90.73% of the stock is owned by institutional investors.
About Zoetis
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Read More
Should you invest $1,000 in Zoetis right now?
Before you consider Zoetis, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Zoetis wasn’t on the list.
While Zoetis currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
